About
Incisive Technologies is a medical device company focussed on empowering oral healthcare professionals and increasing the opportunity for preventative treatments globally.
Founded in 2012, Incisive’s lead technology leverages research by Dr Jonathan Mangum, company CSO and Director, conducted at The University of Melbourne. The research focussed on understanding enamel decay with the aim of improving clinical outcomes for patients. The research into the detection of caries lead to granted patents, including 22 jurisdictions across Americas, Europe and the Asia-Pacific.
Company growth has been significant in recent years, facilitated by a successful partnership with CareQuest Innovation Partners (Boston), the leading dental advocacy group in the US, and an AusIndustry Accelerating Commercialisation grant. These have propelled Incisive's towards translation, scale-up readying for commercialisation and entry into the US Market following FDA 510k Clearance in May 2023.
BlueCheck is the first product to be commercialised by Incisive Technologies. We are committed to advancing improved caries management and will continue to work with leading clinicians and academics to support the drive towards prevention and minimally invasive care. Incisive has a number of research and collaboration projects to understand BlueCheck’s role in clinical management and how it can make early caries detection simple.
The US market is our first launch market, representing a sizable opportunity, with over 225 million routine dental check-ups per annum. We are building our US team to support bringing BlueCheck to market and driving the evolution of oral care. We are always looking for talent with a shared passion to advancing oral healthcare to address the global challenge of tooth decay.
“We’ve worked directly with dentists, orthodontists, collaborators and experienced investors to understand how novel technologies can support the shift to better care and improve patient outcomes. Early detection of dental caries and the differentiation of their activity status are keys to success and de-risk the challenges with caries diagnosis. BlueCheck gives the clinician objective evidence in detecting and monitoring early caries. Our aim is to help simplify the management of caries”
Early 2023, we launched our new medical device manufacturing facility in Melbourne, Australia. This purpose-built facility, designed and constructed with key partners CBE Pure Solutions and BioConstruct, aligns with Incisive’s values, supporting direct manufacture, to expand the value chain and keep capabilities locally in Australia.